5 European Projects Found
Searched on 125080 European Projects
FINISHED
Optomechanics for Virology (VIRUSCAN)
Start date: Nov 1, 2016, End date: Oct 31, 2021,
Viral infections diagnosis demands novel, cheaper and rapid technologies to overcome present constraints. Current gold standard for diagnosis of viral infections is based on pathogen-targeted nucleic acid identification; thus, it cannot discern infectious stages from latent ones and it demands time consuming adjustments when mutations occur or new emerging viruses are to be included in the diagnos ...
Read Project
10
Partners Participants
FINISHED
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)
Start date: Jan 1, 2016, End date: Dec 31, 2020,
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Read Project
43
Partners Participants
FINISHED
Evaluation of species-specific ebolavirus pathophysiology in xenochimeric mice (EBOPATH)
Start date: Nov 1, 2016, End date: Oct 31, 2018,
Ebolaviruses comprise five virus species of which at least three are highly pathogenic for humans. Other mammalian species such as non-human primates, forest antelopes and pigs are susceptible to ebolavirus infection with different degree of severity. However, bats and laboratory mice are entirely resistant to ebolaviruses. Why do ebolaviruses cause severe disease in some species but not others? T ...
Read Project
1
Partner Participant
FINISHED
Assessment of functional immune responses of HIV infected individuals without protective HLA-B alleles (HIV-NOPA)
Start date: Jan 1, 2015, End date: Dec 31, 2017,
"Infection with the human immunodeficiency virus (HIV) is eventually fatal in the absence of antiretroviral therapy. However, approximately 0.3% of patients have the ability to efficiently control the virus for long periods without treatment (elite controllers). It has been shown that HLA class I restricted CD8+ T cells play a crucial role in this process. There is a strong genetic association bet ...
Read Project
1
Partner Participant
FINISHED
New drugs targeting influenza virus polymerase (FLU-PHARM)
Start date: Nov 1, 2010, End date: Apr 30, 2015,
The 2009 H1N1 pandemic and the ongoing threat of highly pathogenic H5N1 strains have focused attention worldwide on the urgent need for effective anti-influenza drug options when the public is not protected by vaccination. The need is pressing since several circulating strains are resistant to currently stock-piled anti-neuraminidase drugs. In this project, we will exploit our recent advances in t ...
Read Project
